The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome

Metabolism: Clinical and Experimental

Volumn 65, Issue 8, 2016, Pages 1196-1207

  Aguilar Olivos, Nancy E ^a   Almeda Valdes, Paloma ^b   Aguilar Salinas, Carlos A ^b   Uribe, Misael ^a   Méndez Sánchez, Nahum ^a  

^a LIVER RESEARCH UNIT   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Fatty liver; Fibrosis; Metabolic syndrome; Obesity; Therapeutics

Indexed keywords

AMINOTRANSFERASE; LIPID;

BARIATRIC SURGERY; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; DISEASE ASSOCIATION; ENDOSCOPIC THERAPY; FATTY LIVER; FOLLOW UP; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; MORBID OBESITY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; REVIEW; SURGICAL PATIENT; WEIGHT REDUCTION; BLOOD; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; PATHOLOGY; TREATMENT OUTCOME;

BARIATRIC SURGERY; HUMANS; INSULIN RESISTANCE; LIPIDS; LIVER; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; TREATMENT OUTCOME;

EID: 84978910811     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2015.09.004     Document Type: Review

References (100)

1. [1] Almeda-Valdes, P., Aguilar-Olivos, N., Uribe, M., Mendez-Sanchez, N., Common features of the metabolic syndrome and nonalcoholic fatty liver disease. Rev Recent Clin Trials 9:3 (2014), 148–158.
2. [2] Schuppan, D., Schattenberg, J.M., Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol 28:Suppl. 1 (2013), 68–76.
3. [3] Ong, J.P., Elariny, H., Collantes, R., Younoszai, A., Chandhoke, V., Reines, H.D., et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 15:3 (2005), 310–315.
4. [4] Singh, S., Allen, A.M., Wang, Z., Prokop, L.J., Murad, M.H., Loomba, R., Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13:4 (2015), 643–654 [1-649; quiz e639-640].
5. [5] Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142:7 (2012), 1592–1609.
6. [6] Abenavoli, L., Milic, N., Peta, V., Alfieri, F., De Lorenzo, A., Bellentani, S., Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. World J Gastroenterol 20:45 (2014), 16831–16840.
7. [7] Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P., Loria, P., Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 47:3 (2015), 181–190.
8. [8] Rinella, M.E., Nonalcoholic fatty liver disease: a systematic review. JAMA 313:22 (2015), 2263–2273.
9. [9] Browning, J.D., Horton, J.D., Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114:2 (2004), 147–152.
10. [10] Sasaki, A., Nitta, H., Otsuka, K., Umemura, A., Baba, S., Obuchi, T., et al. Bariatric surgery and non-alcoholic fatty liver disease: current and potential future treatments. Front Endocrinol, 5, 2014, 164, 10.3389/fendo.2014.00164.
11. [11] Laferrere, B., Effect of gastric bypass surgery on the incretins. Diabetes Metab 35:6 Pt 2 (2009), 513–517.
12. [12] Acosta, A., Abu Dayyeh, B.K., Port, J.D., Camilleri, M., Recent advances in clinical practice challenges and opportunities in the management of obesity. Gut 63:4 (2014), 687–695.
13. [13] Ionut, V., Burch, M., Youdim, A., Bergman, R.N., Gastrointestinal hormones and bariatric surgery-induced weight loss. Obesity 21:6 (2013), 1093–1103.
14. [14] Kong, L.C., Tap, J., Aron-Wisnewsky, J., Pelloux, V., Basdevant, A., Bouillot, J.L., et al. Gut microbiota after gastric bypass in human obesity: increased richness and associations of bacterial genera with adipose tissue genes. Am J Clin Nutr 98:1 (2013), 16–24.
15. [15] Sweeney, T.E., Morton, J.M., The human gut microbiome: a review of the effect of obesity and surgically induced weight loss. JAMA Surg 148:6 (2013), 563–569.
16. [16] Aron-Wisnewsky, J., Clement, K., The effects of gastrointestinal surgery on gut microbiota: potential contribution to improved insulin sensitivity. Curr Atheroscler Rep, 16(11), 2014, 454, 10.1007/s11883-014-0454-9.
17. [17] NIH conference. Gastrointestinal surgery for severe obesity, Consensus Development Conference Panel. Ann Intern Med 115:12 (1991), 956–961.
18. [18] Mingrone, G., Castagneto, M., Bariatric surgery: unstressing or boosting the beta-cell?. Diabetes Obes Metab 11:Suppl. 4 (2009), 130–142.
19. [19] Pories, W.J., Caro, J.F., Flickinger, E.G., Meelheim, H.D., Swanson, M.S., The control of diabetes mellitus (NIDDM) in the morbidly obese with the Greenville Gastric Bypass. Ann Surg 206:3 (1987), 316–323.
20. [20] Pories, W.J., Flickinger, E.G., Meelheim, D., Van Rij, A.M., Thomas, F.T., The effectiveness of gastric bypass over gastric partition in morbid obesity: consequence of distal gastric and duodenal exclusion. Ann Surg 196:4 (1982), 389–399.
21. [21] Pories, W.J., MacDonald, K.G. Jr., Flickinger, E.G., Dohm, G.L., Sinha, M.K., Barakat, H.A., et al. Is type II diabetes mellitus (NIDDM) a surgical disease?. Ann Surg 215:6 (1992), 633–642 [discussion 643].
22. [22] Pories, W.J., MacDonald, K.G. Jr., Morgan, E.J., Sinha, M.K., Dohm, G.L., Swanson, M.S., et al. Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. Am J Clin Nutr 55:2 Suppl (1992), 582S–585S.
23. [23] Pories, W.J., Swanson, M.S., MacDonald, K.G., Long, S.B., Morris, P.G., Brown, B.M., et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg 222:3 (1995), 339–350 [discussion 350–332].
24. [24] Brolin, R.E., Kenler, H.A., Gorman, J.H., Cody, R.P., Long-limb gastric bypass in the superobese. A prospective randomized study. Ann Surg 215:4 (1992), 387–395.
25. [25] Brolin, R.E., Robertson, L.B., Kenler, H.A., Cody, R.P., Weight loss and dietary intake after vertical banded gastroplasty and Roux-en-Y gastric bypass. Ann Surg 220:6 (1994), 782–790.
26. [26] Sugerman, H.J., Wolfe, L.G., Sica, D.A., Clore, J.N., Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg 237:6 (2003), 751–756 [discussion 757–758].
27. [27] Schauer, P.R., Burguera, B., Ikramuddin, S., Cottam, D., Gourash, W., Hamad, G., et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 238:4 (2003), 467–484 [discussion 484–465].
28. [28] Aminian, A., Brethauer, S.A., Daigle, C.R., Kirwan, J.P., Burguera, B., Kashyap, S.R., et al. Outcomes of bariatric surgery in type 2 diabetic patients with diminished pancreatic secretory reserve. Acta Diabetol 51:6 (2014), 1077–1079.
29. [29] Ikramuddin, S., Billington, C.J., Lee, W.J., Bantle, J.P., Thomas, A.J., Connett, J.E., et al. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. Lancet Diabetes Endocrinol 3:6 (2015), 413–422.
30. [30] Sjostrom, C.D., Peltonen, M., Sjostrom, L., Blood pressure and pulse pressure during long-term weight loss in the obese: the Swedish Obese Subjects (SOS) Intervention Study. Obes Res 9:3 (2001), 188–195.
31. [31] Schauer, P.R., Kashyap, S.R., Wolski, K., Brethauer, S.A., Kirwan, J.P., Pothier, C.E., et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 366:17 (2012), 1567–1576.
32. [32] Schauer, P.R., Bhatt, D.L., Kirwan, J.P., Wolski, K., Brethauer, S.A., Navaneethan, S.D., et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med 370:21 (2014), 2002–2013.
33. [33] Adami, G.F., Papadia, F., Carlini, F., Murelli, F., Scopinaro, N., Effect of biliopancreatic diversion on hypertension in severely obese patients. Hypertens Res 28:2 (2005), 119–123.
34. [34] Scopinaro, N., Marinari, G.M., Camerini, G.B., Papadia, F.S., Adami, G.F., Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care 28:10 (2005), 2406–2411.
35. [35] Dixon, J.B., O'Brien, P.E., Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. Diabetes Care 25:2 (2002), 358–363.
36. [36] Pontiroli, A.E., Pizzocri, P., Librenti, M.C., Vedani, P., Marchi, M., Cucchi, E., et al. Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. J Clin Endocrinol Metab 87:8 (2002), 3555–3561.
37. [37] Dixon, J.B., O'Brien, P.E., Playfair, J., Chapman, L., Schachter, L.M., Skinner, S., et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 299:3 (2008), 316–323.
38. [38] Chavez-Tapia, N.C., Tellez-Avila, F.I., Barrientos-Gutierrez, T., Mendez-Sanchez, N., Lizardi-Cervera, J., Uribe, M., Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev, 1, 2010, CD007340.
39. [39] Mummadi, R.R., Kasturi, K.S., Chennareddygari, S., Sood, G.K., Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 6:12 (2008), 1396–1402.
40. [40] Vest, A.R., Heneghan, H.M., Agarwal, S., Schauer, P.R., Young, J.B., Bariatric surgery and cardiovascular outcomes: a systematic review. Heart 98:24 (2012), 1763–1777.
41. [41] Puzziferri, N., Roshek, T.B. III, Mayo, H.G., Gallagher, R., Belle, S.H., Livingston, E.H., Long-term follow-up after bariatric surgery: a systematic review. JAMA 312:9 (2014), 934–942.
42. [42] Sjostrom, L., Lindroos, A.K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B., et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351:26 (2004), 2683–2693.
43. [43] Padilla, N., Maraninchi, M., Beliard, S., Berthet, B., Nogueira, J.P., Wolff, E., et al. Effects of bariatric surgery on hepatic and intestinal lipoprotein particle metabolism in obese, nondiabetic humans. Arterioscler Thromb Vasc Biol 34:10 (2014), 2330–2337.
44. [44] Julve, J., Pardina, E., Perez-Cuellar, M., Ferrer, R., Rossell, J., Baena-Fustegueras, J.A., et al. Bariatric surgery in morbidly obese patients improves the atherogenic qualitative properties of the plasma lipoproteins. Atherosclerosis 234:1 (2014), 200–205.
45. [45] Mannisto, V.T., Simonen, M., Soininen, P., Tiainen, M., Kangas, A.J., Kaminska, D., et al. Lipoprotein subclass metabolism in nonalcoholic steatohepatitis. J Lipid Res 55:12 (2014), 2676–2684.
46. [46] Zhou, H., Hylemon, P.B., Bile acids are nutrient signaling hormones. Steroids 86 (2014), 62–68.
47. [47] Patel, V.J., Joharapurkar, A.A., Shah, G.B., Jain, M.R., Effect of GLP-1 based therapies on diabetic dyslipidemia. Curr Diabetes Rev 10:4 (2014), 238–250.
48. [48] Mokadem, M., Zechner, J.F., Margolskee, R.F., Drucker, D.J., Aguirre, V., Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency. Mol Metab 3:2 (2014), 191–201.
49. [49] Joao Cabrera, E., Valezi, A.C., Delfino, V.D., Lavado, E.L., Barbosa, D.S., Reduction in plasma levels of inflammatory and oxidative stress indicators after Roux-en-Y gastric bypass. Obes Surg 20:1 (2010), 42–49.
50. [50] Poitou, C., Perret, C., Mathieu, F., Truong, V., Blum, Y., Durand, H., et al. Bariatric surgery induces disruption in inflammatory signaling pathways mediated by immune cells in adipose tissue: a RNA-Seq study. PLoS One, 10(5), 2015, e0125718.
51. [51] Machado, M.V., Cortez-Pinto, H., Management of fatty liver disease with the metabolic syndrome. Expert Rev Gastroenterol Hepatol 8:5 (2014), 487–500.
52. [52] Lonardo, A., Ballestri, S., Targher, G., Loria, P., Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 9:5 (2015), 629–650.
53. [53] Sjostrom, L., Narbro, K., Sjostrom, C.D., Karason, K., Larsson, B., Wedel, H., et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357:8 (2007), 741–752.
54. [54] Kwok, C.S., Pradhan, A., Khan, M.A., Anderson, S.G., Keavney, B.D., Myint, P.K., et al. Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis. Int J Cardiol 173:1 (2014), 20–28.
55. [55] Caiazzo, R., Lassailly, G., Leteurtre, E., Baud, G., Verkindt, H., Raverdy, V., et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study. Ann Surg 260:5 (2014), 893–898 [discussion 898–899].
56. [56] Quercia, I., Dutia, R., Kotler, D.P., Belsley, S., Laferrere, B., Gastrointestinal changes after bariatric surgery. Diabetes Metab 40:2 (2014), 87–94.
57. [57] Clark, J.M., Alkhuraishi, A.R., Solga, S.F., Alli, P., Diehl, A.M., Magnuson, T.H., Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res 13:7 (2005), 1180–1186.
58. [58] Adams, L.A., Lymp, J.F., St Sauver, J., Sanderson, S.O., Lindor, K.D., Feldstein, A., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129:1 (2005), 113–121.
59. [59] Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:6 (2005), 1313–1321.
60. [60] Brunt, E.M., Kleiner, D.E., Wilson, L.A., Belt, P., Neuschwander-Tetri, B.A., Network, N.C.R., Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53:3 (2011), 810–820.
61. [61] Mathurin, P., Hollebecque, A., Arnalsteen, L., Buob, D., Leteurtre, E., Caiazzo, R., et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 137:2 (2009), 532–540.
62. [62] Lassailly, G., Caiazzo, R., Buob, D., Pigeyre, M., Verkindt, H., Labreuche, J., et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 149:2 (2015), 379–388.
63. [63] Glass, L.M., Dickson, R.C., Anderson, J.C., Suriawinata, A.A., Putra, J., Berk, B.S., et al. Total body weight loss of >/= 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci 60:4 (2015), 1024–1030.
64. [64] El-Kamary, S.S., Mohamed, M.M., El-Raziky, M., Shardell, M.D., Shaker, O.G., ElAkel, W.A., et al. Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection. Liver Int 33:7 (2013), 982–990.
65. [65] Moschen, A.R., Molnar, C., Wolf, A.M., Weiss, H., Graziadei, I., Kaser, S., et al. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol 51:4 (2009), 765–777.
66. [66] Bower, G., Toma, T., Harling, L., Jiao, L.R., Efthimiou, E., Darzi, A., et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg, 2015 Apr 29 [Epub ahead of print].
67. [67] Hassan, M.M., Abdel-Wahab, R., Kaseb, A., Shalaby, A., Phan, A.T., El-Serag, H.B., et al. Obesity early in adulthood increases risk but does not affect outcomes of hepatocellular carcinoma. Gastroenterology 149:1 (2015), 119–129.
68. [68] Wang, C.H., Wey, K.C., Mo, L.R., Chang, K.K., Lin, R.C., Kuo, J.J., Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma. Asian Pac J Cancer Prev 16:9 (2015), 3595–3604.
69. [69] Parikh, M.S., Laker, S., Weiner, M., Hajiseyedjavadi, O., Ren, C.J., Objective comparison of complications resulting from laparoscopic bariatric procedures. J Am Coll Surg 202:2 (2006), 252–261.
70. [70] Therapy AATFoEB, Ginsberg, G.G., Chand, B., Cote, G.A., Dallal, R.M., Edmundowicz, S.A., et al. A pathway to endoscopic bariatric therapies. Gastrointest Endosc 74:5 (2011), 943–953.
71. [71] Kumbhari, V., Oberbach, A., Nimgaonkar, A., Primary endoscopic therapies for obesity and metabolic diseases. Curr Opin Gastroenterol 31:5 (2015), 351–358.
72. [72] Mui, W.L., Ng, E.K., Tsung, B.Y., Lam, C.H., Yung, M.Y., Impact on obesity-related illnesses and quality of life following intragastric balloon. Obes Surg 20:8 (2010), 1128–1132.
73. [73] Lee, Y.M., Low, H.C., Lim, L.G., Dan, Y.Y., Aung, M.O., Cheng, C.L., et al. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastrointest Endosc 76:4 (2012), 756–760.
74. [74] Hall, J.C., Watts, J.M., O'Brien, P.E., Dunstan, R.E., Walsh, J.F., Slavotinek, A.H., et al. Gastric surgery for morbid obesity. The Adelaide Study. Ann Surg 211:4 (1990), 419–427.
75. [75] Schauer, P.R., Ikramuddin, S., Gourash, W., Ramanathan, R., Luketich, J., Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg 232:4 (2000), 515–529.
76. [76] Sjostrom, C.D., Peltonen, M., Wedel, H., Sjostrom, L., Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 36:1 (2000), 20–25.
77. [77] Nannipieri, M., Mari, A., Anselmino, M., Baldi, S., Barsotti, E., Guarino, D., et al. The role of beta-cell function and insulin sensitivity in the remission of type 2 diabetes after gastric bypass surgery. J Clin Endocrinol Metab 96:9 (2011), E1372–E1379.
78. [78] Carlsson, L.M., Peltonen, M., Ahlin, S., Anveden, A., Bouchard, C., Carlsson, B., et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 367:8 (2012), 695–704.
79. [79] Sjostrom, L., Peltonen, M., Jacobson, P., Ahlin, S., Andersson-Assarsson, J., Anveden, A., et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 311:22 (2014), 2297–2304.
80. [80] Rodieux, F., Giusti, V., D'Alessio, D.A., Suter, M., Tappy, L., Effects of gastric bypass and gastric banding on glucose kinetics and gut hormone release. Obesity 16:2 (2008), 298–305.
81. [81] Wentworth, J.M., Hensman, T., Playfair, J., Laurie, C., Ritchie, M.E., Brown, W.A., et al. Laparoscopic adjustable gastric banding and progression from impaired fasting glucose to diabetes. Diabetologia 57:3 (2014), 463–468.
82. [82] Froylich, D., Corcelles, R., Daigle, C., Boules, M., Brethauer, S., Schauer, P., Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study. Surg Obes Relat Dis, 2015 Apr 8, 10.1016/j.soard.2015.04.004 [Epub ahead of print].
83. [83] Cazzo, E., Jimenez, L.S., Pareja, J.C., Chaim, E.A., Effect of Roux-en-Y gastric bypass on nonalcoholic fatty liver disease evaluated through NAFLD fibrosis score: a prospective study. Obes Surg 25:6 (2015), 982–985.
84. [84] Tai, C.M., Huang, C.K., Hwang, J.C., Chiang, H., Chang, C.Y., Lee, C.T., et al. Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients. Obes Surg 22:7 (2012), 1016–1021.
85. [85] Liu, X., Lazenby, A.J., Clements, R.H., Jhala, N., Abrams, G.A., Resolution of nonalcoholic steatohepatits after gastric bypass surgery. Obes Surg 17:4 (2007), 486–492.
86. [86] Furuya, C.K. Jr., de Oliveira, C.P., de Mello, E.S., Faintuch, J., Raskovski, A., Matsuda, M., et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol 22:4 (2007), 510–514.
87. [87] de Almeida, S.R., Rocha, P.R., Sanches, M.D., Leite, V.H., da Silva, R.A., Diniz, M.T., et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes Surg 16:3 (2006), 270–278.
88. [88] Csendes, A., Smok, G., Burgos, A.M., Histological findings in the liver before and after gastric bypass. Obes Surg 16:5 (2006), 607–611.
89. [89] Barker, K.B., Palekar, N.A., Bowers, S.P., Goldberg, J.E., Pulcini, J.P., Harrison, S.A., Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am J Gastroenterol 101:2 (2006), 368–373.
90. [90] Mottin, C.C., Moretto, M., Padoin, A.V., Kupski, C., Swarowsky, A.M., Glock, L., et al. Histological behavior of hepatic steatosis in morbidly obese patients after weight loss induced by bariatric surgery. Obes Surg 15:6 (2005), 788–793.
91. [91] Caiazzo, R., Arnalsteen, L., Pigeyre, M., Dezfoulian, G., Verkindt, H., Kirkby-Bott, J., et al. Long-term metabolic outcome and quality of life after laparoscopic adjustable gastric banding in obese patients with type 2 diabetes mellitus or impaired fasting glucose. Br J Surg 97:6 (2010), 884–891.
92. [92] Dixon, J.B., Bhathal, P.S., O'Brien, P.E., Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes Surg 16:10 (2006), 1278–1286.
93. [93] Stratopoulos, C., Papakonstantinou, A., Terzis, I., Spiliadi, C., Dimitriades, G., Komesidou, V., et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg 15:8 (2005), 1154–1160.
94. [94] Luyckx, F.H., Desaive, C., Thiry, A., Dewe, W., Scheen, A.J., Gielen, J.E., et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 22:3 (1998), 222–226.
95. [95] Meinhardt, N.G., Souto, K.E., Ulbrich-Kulczynski, J.M., Stein, A.T., Hepatic outcomes after jejunoileal bypass: is there a publication bias?. Obes Surg 16:9 (2006), 1171–1178.
96. [96] Praveen Raj, P., Gomes, R.M., Kumar, S., Senthilnathan, P., Karthikeyan, P., Shankar, A., et al. The effect of surgically induced weight loss on nonalcoholic fatty liver disease in morbidly obese Indians: “NASHOST” prospective observational trial. Surg Obes Relat Dis, 2015, 10.1016/j.soard.2015.02.006 [Epub ahead of print].
97. [97] Taitano, A.A., Markow, M., Finan, J.E., Wheeler, D.E., Gonzalvo, J.P., Murr, M.M., Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointest Surg 19:3 (2015), 429–436 [discussion 436–427].
98. [98] Mattar, S.G., Velcu, L.M., Rabinovitz, M., Demetris, A.J., Krasinskas, A.M., Barinas-Mitchell, E., et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 242:4 (2005), 610–617 [discussion 618–620].
99. [99] Moretto, M., Kupski, C., da Silva, V.D., Padoin, A.V., Mottin, C.C., Effect of bariatric surgery on liver fibrosis. Obes Surg 22:7 (2012), 1044–1049.
100. [100] Weiner, R.A., Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig Dis 28:1 (2010), 274–279.